Key Points
- Howard Horn sold 3,081 shares of Ultragenyx on Dec. 10 at an average of $36.38 for $112,086.78, trimming his stake by 3.14% to 95,146 shares (he also sold 7,942 shares on Oct. 13).
- Q3 results missed estimates — Ultragenyx reported ($1.81) EPS versus ($1.23) expected and revenue of $159.93M versus $167.42M, though revenue rose 14.6% year-over-year and the company remains unprofitable with negative ROE and net margin.
- Analyst sentiment and ownership — the stock carries a "Moderate Buy" consensus with an average target of $80.23 (12 Buys, 1 Hold, 1 Sell), a market cap of about $3.5B, and roughly 97.67% institutional ownership.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 3,081 shares of the business's stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the transaction, the chief financial officer owned 95,146 shares of the company's stock, valued at $3,461,411.48. The trade was a 3.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Howard Horn also recently made the following trade(s):
- On Monday, October 13th, Howard Horn sold 7,942 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $31.51, for a total transaction of $250,252.42.
Ultragenyx Pharmaceutical Price Performance
NASDAQ RARE opened at $36.28 on Friday. The business has a fifty day moving average price of $33.36 and a two-hundred day moving average price of $32.43. The stock has a market capitalization of $3.50 billion, a PE ratio of -6.11 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $47.12.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The business had revenue of $159.93 million for the quarter, compared to analyst estimates of $167.42 million. During the same period last year, the firm posted ($1.40) EPS. Ultragenyx Pharmaceutical's quarterly revenue was up 14.6% on a year-over-year basis. As a group, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on RARE shares. Wells Fargo & Company began coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, October 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Barclays dropped their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, November 24th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Finally, Truist Financial lowered their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, November 5th. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $80.23.
Read Our Latest Stock Analysis on RARE
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of RARE. Jacobs Levy Equity Management Inc. boosted its stake in Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock worth $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Norges Bank acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $35,765,000. Adage Capital Partners GP L.L.C. boosted its holdings in Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock worth $77,815,000 after acquiring an additional 965,919 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Ultragenyx Pharmaceutical by 439.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company's stock worth $42,314,000 after acquiring an additional 947,865 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Ultragenyx Pharmaceutical in the third quarter valued at approximately $22,560,000. Institutional investors and hedge funds own 97.67% of the company's stock.
About Ultragenyx Pharmaceutical
(
Get Free Report)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
